Neovacs announced that the company has signed a new supply agreement with the biosyn GmbH to diversify its sourcing of KLH, one of the three components required to manufacture its therapeutic vaccine IFNa Kinoid. As a pre-requisite to this supply agreement, Neovacs has validated the protein produced by biosyn GmbH to meet the needs for the development of the manufacturing process of the IFNa Kinoid vaccine and the phase III clinical batches requirements, as well as for the future market launch.